JPWO2020132096A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020132096A5 JPWO2020132096A5 JP2021534983A JP2021534983A JPWO2020132096A5 JP WO2020132096 A5 JPWO2020132096 A5 JP WO2020132096A5 JP 2021534983 A JP2021534983 A JP 2021534983A JP 2021534983 A JP2021534983 A JP 2021534983A JP WO2020132096 A5 JPWO2020132096 A5 JP WO2020132096A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fucosylation
- antibody derivative
- derivative
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004965 antibodies Human genes 0.000 claims description 99
- 108090001123 antibodies Proteins 0.000 claims description 99
- 230000033581 fucosylation Effects 0.000 claims description 47
- 210000004027 cells Anatomy 0.000 claims description 30
- 239000003112 inhibitor Substances 0.000 claims description 16
- 230000002401 inhibitory effect Effects 0.000 claims description 16
- IRKXGKIPOMIQOD-ZZWDRFIYSA-N (3S,4R,5S,6S)-3-fluoro-6-methyloxane-2,4,5-triol Chemical group C[C@@H]1OC(O)[C@@H](F)[C@H](O)[C@@H]1O IRKXGKIPOMIQOD-ZZWDRFIYSA-N 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 8
- 150000008267 fucoses Chemical class 0.000 claims description 8
- 238000009738 saturating Methods 0.000 claims description 6
- PNNNRSAQSRJVSB-SLPGGIOYSA-N (2S,3S,4R,5S)-2,3,4,5-tetrahydroxyhexanal Chemical group C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 4
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-Acetylglucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 4
- 229950006780 N-Acetylglucosamine Drugs 0.000 claims description 4
- 230000010261 cell growth Effects 0.000 claims description 4
- 210000004408 Hybridomas Anatomy 0.000 claims description 3
- 150000001720 carbohydrates Chemical group 0.000 claims description 3
- 241000699802 Cricetulus griseus Species 0.000 claims description 2
- 102000018358 Immunoglobulins Human genes 0.000 claims description 2
- 108060003951 Immunoglobulins Proteins 0.000 claims description 2
- 210000001672 Ovary Anatomy 0.000 claims description 2
- 238000005349 anion exchange Methods 0.000 claims description 2
- 238000005341 cation exchange Methods 0.000 claims description 2
- 230000002209 hydrophobic Effects 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 108020001756 ligand binding domains Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 210000003292 kidney cell Anatomy 0.000 claims 3
- 230000004663 cell proliferation Effects 0.000 claims 2
- 241000282693 Cercopithecidae Species 0.000 claims 1
- 241000699800 Cricetinae Species 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 230000001154 acute Effects 0.000 claims 1
- 229930002945 all-trans-retinaldehyde Natural products 0.000 claims 1
- 210000002919 epithelial cells Anatomy 0.000 claims 1
- 201000006439 lymphocytic leukemia Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 230000002207 retinal Effects 0.000 claims 1
- 235000020945 retinal Nutrition 0.000 claims 1
- 239000011604 retinal Substances 0.000 claims 1
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862781691P | 2018-12-19 | 2018-12-19 | |
| US62/781,691 | 2018-12-19 | ||
| PCT/US2019/067222 WO2020132096A1 (en) | 2018-12-19 | 2019-12-18 | Controlled fucosylation of antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022514299A JP2022514299A (ja) | 2022-02-10 |
| JPWO2020132096A5 true JPWO2020132096A5 (de) | 2022-12-20 |
Family
ID=71100565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021534983A Pending JP2022514299A (ja) | 2018-12-19 | 2019-12-18 | 抗体の制御されたフコシル化 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220081477A1 (de) |
| EP (1) | EP3897664A4 (de) |
| JP (1) | JP2022514299A (de) |
| KR (1) | KR20210104837A (de) |
| CN (1) | CN113438951A (de) |
| AU (1) | AU2019402923A1 (de) |
| CA (1) | CA3123591A1 (de) |
| IL (1) | IL284086A (de) |
| MX (1) | MX2021007327A (de) |
| SG (1) | SG11202106481SA (de) |
| WO (1) | WO2020132096A1 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023548767A (ja) * | 2020-10-15 | 2023-11-21 | アムジエン・インコーポレーテツド | 抗体製造方法における相対不対グリカン |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013201195A1 (en) * | 2006-10-24 | 2013-03-21 | Emergent Product Development Seattle, Llc | A method for increasing antibody-dependent cytotoxicity with castanospermine |
| PL2282773T3 (pl) * | 2008-05-02 | 2014-08-29 | Seattle Genetics Inc | Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej |
| US20120258496A1 (en) * | 2010-09-27 | 2012-10-11 | Boehringer Ingelheim International Gmbh | Production of low fucose antibodies in h4-ii-e rat cells |
| PL3212230T3 (pl) * | 2014-10-29 | 2021-07-26 | Seagen Inc. | Dawkowanie i podawanie niefukozylowanych przeciwciał anty-CD40 |
| WO2017096274A1 (en) * | 2015-12-04 | 2017-06-08 | Seattle Genetics, Inc. | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor |
| JP6674028B2 (ja) * | 2016-01-06 | 2020-04-01 | アウトルック セラピューティクス，インコーポレイティド | モノクローナル抗体組成物中のアフコシル化種の調節 |
| JP7152309B2 (ja) * | 2016-02-17 | 2022-10-12 | シージェン インコーポレイテッド | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
| EP3257866A1 (de) * | 2016-06-17 | 2017-12-20 | Academisch Medisch Centrum | Modifizierter anti-tnf-antikörper und verwendung davon bei der behandlung von entzündlicher darmerkrankung |
-
2019
- 2019-12-18 SG SG11202106481SA patent/SG11202106481SA/en unknown
- 2019-12-18 JP JP2021534983A patent/JP2022514299A/ja active Pending
- 2019-12-18 AU AU2019402923A patent/AU2019402923A1/en active Pending
- 2019-12-18 US US17/309,778 patent/US20220081477A1/en active Pending
- 2019-12-18 KR KR1020217022526A patent/KR20210104837A/ko unknown
- 2019-12-18 CA CA3123591A patent/CA3123591A1/en active Pending
- 2019-12-18 CN CN201980092085.1A patent/CN113438951A/zh active Pending
- 2019-12-18 WO PCT/US2019/067222 patent/WO2020132096A1/en unknown
- 2019-12-18 MX MX2021007327A patent/MX2021007327A/es unknown
- 2019-12-18 EP EP19899492.3A patent/EP3897664A4/de active Pending
-
2021
- 2021-06-16 IL IL284086A patent/IL284086A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Fc-engineering for modulated effector functions—improving antibodies for cancer treatment | |
| Jefferis | Glycosylation as a strategy to improve antibody-based therapeutics | |
| Ivarsson et al. | Evaluating the impact of cell culture process parameters on monoclonal antibody N-glycosylation | |
| EP2480561B1 (de) | Kationenaustauschchromatographie | |
| Hristodorov et al. | With or without sugar?(A) glycosylation of therapeutic antibodies | |
| Satoh et al. | Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies | |
| DK2970980T3 (en) | METHODS FOR MANAGING C-TERMINAL LYSIN, GALACTOSE AND SIALINIC ACID CONTENTS IN RECOMBINANT PROTEINS | |
| NO20073662L (no) | Antigenbindende molekyler som binder EGFR, vektorer kodende for disse samt anvendelser derav | |
| WO2010132659A3 (en) | Anti-human cd52 immunoglobulins | |
| US20240101643A1 (en) | In vitro glycoengineering of antibodies | |
| Liu et al. | Impact of IgG fc‐oligosaccharides on recombinant monoclonal antibody structure, stability, safety, and efficacy | |
| JP6457479B2 (ja) | 漏出したアフィニティ精製リガンドの除去 | |
| CA2886753A1 (en) | Compositions and methods for producing glycoproteins | |
| US20200165296A1 (en) | Method for in vitro glycoengineering of antibodies | |
| Chiang et al. | Modulating carbohydrate–protein interactions through glycoengineering of monoclonal antibodies to impact cancer physiology | |
| EA039018B1 (ru) | Квалификационное исследование хроматографической колонки в способах производства для получения композиций на основе антител к il-12/il-23 | |
| JPWO2020132096A5 (de) | ||
| AU2021258023A1 (en) | Methods for modulating protein galactosylation profiles of recombinant proteins using peracetyl galactose | |
| Tayi et al. | Solid‐Phase Enzymatic Remodeling Produces High Yields of Single Glycoform Antibodies | |
| Wagner et al. | Post-HDX deglycosylation of Fc gamma receptor IIIa glycoprotein enables HDX characterization of its binding interface with IgG | |
| US20220349898A1 (en) | Methods of producing antibody compositions | |
| WO2020055900A1 (en) | Methods of modulating antibody-dependent cell-mediated cytotoxicity | |
| Yi et al. | Function characterization of a glyco-engineered anti-EGFR monoclonal antibody cetuximab in vitro | |
| CA3143246A1 (en) | Cell culture methods and compositions for antibody production | |
| Liu et al. | In-Depth Characterization of mAb Charge Variants by On-Line Multidimensional Liquid Chromatography-Mass Spectrometry |